Firefly Luciferase CD19 Knockout NALM6 Cell Line

Products from BPS Bioscience require a minimum order value above 400€

Applications:

• Use as negative control in CAR-T or NK co-culture killing assays.
• In vitro and in vivo bioluminescence imaging.
• Study phenotype changes related to CD19 knockout.
• Introduce further CRISPR/Cas9-based genetic manipulations in order to understand the interplay between CD19 and other partners and pathways.

Background: NALM6 is a human B cell precursor leukemia cell line derived from the peripheral blood of a patient with acute lymphoblastic leukemia. NALM6 is a unique cell line that contains features that allow for highly efficient gene targeting via homologous recombination, the process of random gene shuffling, or nucleotide cross-over.  The cell line also contains a near-diploid karyotype and is easy to transfect, making NALM6 an ideal model for knock-out or knock-in studies of gene functions. The signal generated by the Firefly luciferase is proportional to cell numbers.CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production, such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.

Description: Firefly Luciferase CD19 Knockout NALM6 Cell Line is a NALM6 cell line constitutively expressing Firefly (Photinus pyralis) luciferase under the control of a CMV promoter, in which CD19 (Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) has been genetically removed using CRISPR/Cas9 genome editing using a lentivirus encoding CRISPR/Cas9 gene and sgRNA (single guide RNA) targeting human CD19.

Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.

Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.

Supplied As: Each vial contains ~1 x 10⁶ cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)

Uniprot: P15391

Warnings: Avoid freeze/thaw cycles.

Biosafety Level: BSL-1

References: Li Y., Zuo C., Gu L., 2021Cancer Cell Int. 21(1):623.
Adachi N., Nishijima H., Shibahara K., 2008 Biosci Trends. 2(5):169-180.

• Artikelnummer: BPS82168
• Hersteller: BPS Bioscience
• Hersteller Artikelnummer: 82168
• Verpackungseinheit: 2 vials
• Mengeneinheit: PAK
• Wirt: Human